BeStock  
Stocks › Biotechnology › SLN

Silence Therapeutics SLN

US equityMarket cap rank #3022Biotechnology
$19.81 +$0.00 (0.00%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $19.81 0.00%
Open$19.81
Prev close$19.81
Day range$19.80 – $19.83
Volume399.1K
Market cap$1.23B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±1.3%last 7 reports
Closed higher0 of 70% of the time
Best reaction+0.0%
Worst reaction-5.2%

Stock move on the day after each report

+0.0%2020/Q2+0.0%2020/Q4+0.0%2021/Q2-1.7%2021/Q4-5.2%2022/Q4-1.1%2023/Q4-1.0%2024/Q4
QuarterReport dateTimingImplied moveActual moveVersus implied
2024/Q427 Feb 2025Pre Market±21.6%-1.05%Within range
2023/Q413 Mar 2024Pre Market–-1.12%–
2022/Q415 Mar 2023None–-5.18%–
2021/Q417 Mar 2022None–-1.71%–
2021/Q212 Aug 2021None–+0.00%–
2020/Q430 Mar 2021None–+0.00%–
2020/Q214 Sep 2020None–+0.00%–

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00-100.0% YoY
Operating profit-$14.22M+45.8% YoY
Net profit-$12.43M+40.7% YoY
Diluted EPS-$0.24+46.7% YoY
Free cash flow-$12.78M-17.3% YoY
Operating cash flow-$12.78M

Revenue, last 8 quarters

$25.3MDec '24$142.0KMar '25$224.0KJun '25$159.0KSep '25$34.0KDec '25$422.0KMar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$12.3MDec '24$-28.5MMar '25$-27.4MJun '25$-21.0MSep '25$-11.8MDec '25$-15.0MMar '26$-12.3MJun '26$-12.4MSep '26

Profitability & balance sheet

Gross margin95.0%
Operating margin-12,343.6%
Net margin-11,276.5%
Return on equity-35.6%
Return on assets-24.0%
Return on invested capital-35.5%
Current ratio23.94
Liabilities / assets23.6%
Cash & investments$247.66M
Total debt$0.00
Net cash (debt)$247.66M

Discussion

No comments yet — be the first to weigh in on SLN.

Sign in to join the discussion.

Scroll to Top